dexamethasone (Ozurdex, Allergan)

Role of corticosteroids uncertain in AMD managementThere is no doubt that inflammation is a component of age-related macular degeneration (AMD), and yet the role of corticosteroid treatment in the management of eyes with AMD remains uncertain, said Marc de Smet, MD, PhD.
Anatomic outcome more precise in defining DME treatment failureThe goal of treatment for diabetic macular edema is to maintain or improve vision, but improvement of edema is a better metric for determining whether the treatment is having a benefit or failing.
Study tracks clinical use of dexamethasone implant for DMEA 6-month analysis from the REINFORCE study of the dexamethasone intravitreal implant Ozurdex found an average of one- to two-line vision gains and no new safety concerns.
Latest concepts in steroid therapy for diabetic macular oedemaSteroids are an important second-line treatment for the treatment of diabetic macular oedema. While side effects remain a concern, modern formulations of intravitreal steroid allow the treatment to be tailored to the individual patient.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progressionTreatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
Dexamethasone for DME shows stronger results compared with sham groupUse of an intravitreal implant for diabetic macular edema was more effective than a sham treatment across a variety of parameters in a subanalysis of the MEAD trial.
Real-world experience provides clarity to intravitreal injection misconceptionUsing real-world experience, a retinal surgeon highlights the optimal settings for use of steroid implants for treatment of diabetic macular edema.